Mr. Oelke represents some of the world's preeminent life sciences companies in patent litigation. He also counsels clients on patent and other intellectual property issues in the pharmaceutical, chemical, biotech and mechanical fields.

Mr. Oelke has represented clients in all phases of patent litigation, including appeals to the U.S. Court of Appeals for the Federal Circuit. He has extensive experience in Hatch-Waxman patent litigation. He is a registered patent attorney and has experience before the U.S. Patent and Trademark Office, filing and prosecuting patent applications. He has also conducted due diligence on the patent portfolios of companies.

He has been recognized as a leading attorney in Patent Litigation (Life Sciences/Chemical) in the Legal 500 Vol. II (Intellectual Property, Media, Technology and Telecoms) and in Vol. III (Litigation) (2007). He has also been recognized as a "Future Star" in New York by the Benchmark Litigation Guide (2009).

In addition to lecturing frequently on various patent law issues, he has been cited in Chief Executive magazine concerning changes to the U.S. patent system. "Surviving the Patent Shakeup," Eric Sherman, Chief Executive, July/Aug 2008.

Representative Cases:

• Pfizer Inc. v. Teva Pharmaceuticals, Inc., 2008 WL 518838 (D.N.J. 2008).
• Teva Pharmaceuticals USA, Inc. v. Pfizer Inc., 395 F.3d 1324 (Fed. Cir. 2005).
• Massachusetts Eye & Ear Infirmary v. Novartis Ophthalmics, Inc., 353 F. Supp. 2d 170 (D. Mass 2005).
• Mutual Pharmaceutical Co. v. Pfizer Inc., 307 F. Supp. 2d 88 (D.D.C. 2004).
• ICN Pharmaceuticals, Inc. v. Geneva Pharmaceuticals, Tech. Corp., 272 F. Supp. 2d 1028 (C.D. Cal. 2003).
• Monsanto Co. v. Mycogen Plant Science, 261 F.3d 1356 (Fed. Cir. 2001).